From the newsletter
Between 2021 and 2024, post-Covid, the biggest conversation in African healthcare was the need for vaccine manufacturing capacity. But what happens after the factories are built? Egypt's latest healthcare investments suggest the next phase of Africa's pharmaceutical rise may be about building markets, skills, logistics and procurement systems, not just production capacity.
In April, Egypt launched the Vaccine City, a 115,000-square-metre biotechnology complex that integrates vaccine production, research, logistics and workforce development. The project includes six manufacturing facilities, advanced laboratories and a biotechnology academy to train pharma specialists.
Two months later, Egypt signed agreements with the Africa CDC to host the operational headquarters of the African Pooled Procurement Mechanism (APPM), becoming the first country to host the continent's platform for pooled purchasing of medicines and health products.
More details